An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease

European Respiratory Journal

Volumn 52, Issue 4, 2018, Pages

  Kik, Sandra V ^a,b   Schumacher, Samuel ^c   Cirillo, Daniela Maria ^d   Churchyard, Gavin ^e,f,g   Boehme, Catharina ^c   Goletti, Delia ^h   Rangaka, Molebogeng X ^i,j   Denkinger, Claudia M ^c   Lienhardt, Christian ^k,l   Gilpin, Christopher ^k   Matteelli, Alberto ^m   Cobelens, Frank ^a,b  

^a KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^b AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^c FIND ^*  (Switzerland)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e AURUM INSTITUTE   (South Africa)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^h NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF CAPE TOWN   (South Africa)

^k WORLD HEALTH ORGANIZATION   (Switzerland)

^l INSERM   (France)

^m UNIVERSITY OF BRESCIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EVALUATION; DISEASE COURSE; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HEALTH IMPACT ASSESSMENT; HUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PUBLIC HEALTH; REVIEW; TUBERCULOSIS; DISEASE EXACERBATION; EVALUATION STUDY; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PREDICTIVE VALUE; WORLD HEALTH ORGANIZATION;

DISEASE PROGRESSION; EVALUATION STUDIES AS TOPIC; GUIDELINES AS TOPIC; HUMANS; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 85055617607     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00946-2018     Document Type: Review

References (29)

1. Abu-Raddad LJ, Sabatelli L, Achterberg JT, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA 2009; 106: 13980–13985.
2. Lonnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928–952.
3. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med 2016; 13: e1002152.
4. Getahun H, Matteelli A, Chaisson RE, et al. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015; 372: 2127–2135.
5. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012; 142: 63–75.
6. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 45–55.
7. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015; 46: 1563–1576.
8. World Health Organization. Guideline on the Management of Latent Tuberculosis Infection. Geneva, WHO, 2015.
9. Petruccioli E, Scriba TJ, Petrone L, et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J 2016; 48: 1751–1763.
10. Sloot R, Schim van der Loeff MF, van Zwet EW, et al. Biomarkers can identify pulmonary tuberculosis in HIV-infected drug users months prior to clinical diagnosis. EBioMedicine 2015; 2: 172–179.
11. Suliman S, Thompson E, Sutherland J, et al. Four-gene pan-African blood signature predicts progression to tuberculosis. Am J Respir Crit Care Med 2018; 197: 1198–1208.
12. Cobelens F, Kik S, Esmail H, et al. From latent to patent: rethinking prediction of tuberculosis. Lancet Respir Med 2017; 5: 243–244.
13. World Health Organization, FIND. Consensus Meeting Report. Development of a Target Product Profile (TPP) and a Framework for Evaluation for a Test for Predicting Progression from Tuberculosis Infection to Active Disease (WHO/HTM/TB/2017.18). Geneva, WHO, 2017.
14. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99: 131–138.
15. Zak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 2016; 387: 2312–2322.
16. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013; 42: 252–271.
17. World Health Organization. Handbook for Guideline Development. Geneva, WHO, 2012.
18. European Commission. Regulatory Framework on Medical Devices. 2017. https://ec.europa.eu/growth/sectors/medical-devices/regulatory-framework_en Date last accessed: May 21, 2018.
19. Food and Drug Administration. Human Subject Protection; Acceptance of Data From Clinical Investigations for Medical Devices. Final Rule. Fed Regist 2018; 83: 7366–7388.
20. US food and Drug Administration. Acceptance of Clinical Data to Support Medical Device Applications and Submissions, Frequently Asked Questions, Guidance for Industry and Food and Drug Administration Staff. 2018. www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM597273.pdf Date last accessed: July 17, 2018.
21. Duffy FJ, Thompson E, Downing K, et al. A serum circulating miRNA signature for short-term risk of progression to active tuberculosis among household contacts. Front Immunol 2018; 9: 661.
22. Fiore-Gartland A, Carpp LN, Naidoo K, et al. Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. Tuberculosis 2018; 109: 61–68.
23. Mathad JS, Bhosale R, Balasubramanian U, et al. Quantitative IFN-gamma and IL-2 response associated with latent tuberculosis test discordance in HIV-infected pregnant women. Am J Respir Crit Care Med 2016; 193: 1421–1428.
24. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet 2014; 384: 682–690.
25. Sharma SK, Vashishtha R, Chauhan LS, et al. Comparison of TST and IGRA in diagnosis of latent tuberculosis infection in a high TB-burden setting. PLoS One 2017; 12: e0169539.
26. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2014; 383: 424–435.
27. Hemming K, Haines TP, Chilton PJ, et al. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ 2015; 350: h391.
28. Saunders MJ, Wingfield T, Tovar MA, et al. A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study. Lancet Infect Dis 2017; 17: 1190–1199.
29. Mahomed H, Hawkridge T, Verver S, et al. The tuberculin skin test versus QuantiFERON TB Gold in predicting tuberculosis disease in an adolescent cohort study in South Africa. PLoS One 2011; 6: e17984.